Ruxolitinib Efficacy in Steroid-Refractory Chronic GVHD
A discussion of data from the REACH3 trial and real-world data on the efficacy of ruxolitinib in patients with steroid-refractory chronic GVHD.
Case: A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
- A 42-year-old woman previously underwent myeloablative conditioning and an allogeneic PBSC transplant for acute myeloid leukemia
- Received tacrolimus and methotrexate for GVHD prophylaxis
- At 11 months post-transplant, patient developed moderately dry and painful eyes, mild muscle and joint pain, mild erythematous rash on face and arms
First-line Treatment
- Patient received eye drops, topical steroid cream for rash, and was started on oral prednisone at 0.5 mg/kg/day
- After 4 weeks of treatment, eye dryness resolved, but the patient’s skin rash and muscle/joint pain worsened; steroid dose was increased to 1 mg/kg/day
- Skin rash and muscle/joint pain continued despite increased steroid dose
Second-line Treatment
Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
FDA Approves Remestemcel-L in Pediatric Patients With Acute GVHD
December 18th 2024Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.
Read More
Iomab-B Leads to More Durable Responses vs alloHCT in AML Treatment
September 24th 2024Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs allogeneic cell transplant in older patients with relapsed/refractory acute myeloid leukemia.
Read More
